Primary Site >> Stomach Cancer

Gene >> AXL

Journal: Clin Cancer Res. 1999 Jul;5(7):1745-51.
Title: tie-1 protein tyrosine kinase: a novel independent prognostic marker for gastric cancer.
Author: Lin, W C|Li, A F|Chi, C W|Chung, W W|Huang, C L|Lui, W Y|Kung, H J|Wu, C W
PMID: 10430078
Journal: Anticancer Res. 2002 Mar-Apr;22(2B):1071-8.
Title: Clinical significance of AXL kinase family in gastric cancer.
Author: Wu, Chew-Wun|Li, Anna F Y|Chi, Chin-Wen|Lai, Chun-Hung|Huang, Chen Lung|Lo, Su-Shun|Lui, Wing-Yiu|Lin, Wen-Chang
PMID: 12168903
Journal: Mol Carcinog. 2007 Feb;46(2):155-64.
Title: Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway.
Author: Sawabu, Tateo|Seno, Hiroshi|Kawashima, Tomoko|Fukuda, Akihisa|Uenoyama, Yoshito|Kawada, Mayumi|Kanda, Naoki|Sekikawa, Akira|Fukui, Hirokazu|Yanagita, Motoko|Yoshibayashi, Hiroshi|Satoh, Seiji|Sakai, Yoshiharu|Nakano, Toru|Chiba, Tsutomu
PMID: 17186543
Journal: Invest New Drugs. 2012 Aug;30(4):1352-60.
Title: Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks.
Author: Kataoka, Yu|Mukohara, Toru|Tomioka, Hideo|Funakoshi, Yohei|Kiyota, Naomi|Fujiwara, Yutaka|Yashiro, Masakazu|Hirakawa, Kosei|Hirai, Midori|Minami, Hironobu
PMID: 21655918
Journal: PLoS One. 2013;8(3):e54014.
Title: Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.
Author: Shah, Manish A|Wainberg, Zev A|Catenacci, Daniel V T|Hochster, Howard S|Ford, James|Kunz, Pamela|Lee, Fa-Chyi|Kallender, Howard|Cecchi, Fabiola|Rabe, Daniel C|Keer, Harold|Martin, Anne-Marie|Liu, Yuan|Gagnon, Robert|Bonate, Peter|Liu, Li|Gilmer, Tona|Bott
PMID: 23516391
Journal: Mol Cancer Ther. 2013 Jun;12(6):925-36.
Title: Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion.
Author: Wang, Jing|Pursell, Natalie W|Samson, Maria Elena S|Atoyan, Ruzanna|Ma, Anna W|Selmi, Abdelkader|Xu, Wanlu|Cai, Xiong|Voi, Maurizio|Savagner, Pierre|Lai, Cheng-Jung
PMID: 23536719
Journal: Mol Cancer Ther. 2013 Sep;12(9):1749-62.
Title: S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.
Author: Burbridge, Mike F|Bossard, Celine J|Saunier, Carine|Fejes, Imre|Bruno, Alain|Leonce, Stephane|Ferry, Gilles|Da Violante, Georges|Bouzom, Francois|Cattan, Valerie|Jacquet-Bescond, Anne|Comoglio, Paolo M|Lockhart, Brian P|Boutin, Jean A|Cordi, Alex|Ortuno,
PMID: 23804704
Journal: Clin Cancer Res. 2013 Oct 1;19(19):5275-80.
Title: Molecular pathways: MERTK signaling in cancer.
Author: Cummings, Christopher T|Deryckere, Deborah|Earp, H Shelton|Graham, Douglas K
PMID: 23833304
Journal: Oncol Lett. 2017 Mar;13(3):1826-1834.
Title: High BIM mRNA levels are associated with longer survival in advanced gastric cancer.
Author: Wu, Nandie|Huang, Ying|Zou, Zhengyun|Gimenez-Capitan, Ana|Yu, Lixia|Hu, Wenjing|Zhu, Lijing|Sun, Xia|Sanchez, Jose Javier|Guan, Wenxian|Liu, Baorui|Rosell, Rafael|Wei, Jia
PMID: 28454330
Journal: Oncotarget. 2017 Nov 11;8(62):105727-105734.
Title: MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines.
Author: Kim, Jung Eun|Kim, Youjin|Li, Gary|Kim, Seung Tae|Kim, Kyung|Park, Se Hoon|Park, Joon Oh|Park, Young Suk|Lim, Ho Yeong|Lee, Hyuk|Sohn, Tae Sung|Kim, Kyoung-Mee|Kang, Won Ki|Lee, Jeeyun
PMID: 29285287